Dr. Dara Abacan

Pharmacist



  
  415 N Oak St, Inglewood
California, 90302-3314

 310-671-2600    310-671-2601
Dr. Dara Abacan is a pharmacist in Inglewood, California. Patients can reach her at 415 N Oak St, Inglewood or contact her on 310-671-2600. Active license number of Dr. Dara Abacan is 63538 for Pharmacist in California.
Dr. Dara Abacan is


Complete Profile:
Dr. Dara Abacan speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name: Dr. Dara Abacan
Specialization: Pharmacist
Credentials:PHARMD
Gender:Female
Location:415 N Oak St, Inglewood,
California, 90302-3314
Phone:310-671-2600
Fax:310-671-2601
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Dara Abacan are as mentioned below.
NPI Number: 1639954902
NPI Enumeration Date: 25 Aug, 2023
NPI Last Update On: 25 Aug, 2023

Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Dara Abacan are as mentioned below.
SpecializationLicense NumberStateStatus
Pharmacist 63538CaliforniaPrimary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address: 4752 Amberwood Ave,
La Palma, California
Zip: 90623-1909
Phone Number: 562-841-8284
Patients can reach Dr. Dara Abacan at 415 N Oak St, Inglewood, California or can call on phone at 310-671-2600.

Comments/ Reviews:
Read all the reviews posted for Dr. Dara Abacan below. You may also share your own experience with Dr. Dara Abacan. Your feedback can help others make better decisions.
**Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 08 December, 2025.